Last Friday, shares in Massachusetts headquartered Alnylam Pharmaceuticals Inc. ended the session 1.70% higher at $46.54. The stock recorded a trading volume of 1.21 million shares. The Company's shares have advanced 28.67% in the last month and are trading 14.12% below their 50-day moving average. Moreover, shares of Alnylam Pharma, which discovers, develops, and commercializes novel therapeutics based on RNA interference, have a Relative Strength Index (RSI) of 56.67.
On November 10th, 2016, research firm Leerink Partners resumed its 'Market Perform' rating on the Company's stock.
On November 13th, 2016, Alnylam Pharma and The Medicines Co. announced that results from the Phase 1 study of inclisiran (in-CLEE-si-ran), the recommended International Nonproprietary Name (INN) for ALN-PCSsc, were published in The New England Journal of Medicine (NEJM). Results from the study showed doses ≥300 mg (single or multiple doses) significantly reduced PCSK9 and LDL cholesterol for at least 6 months. Moreover, inclisiran was found to be generally well tolerated. The free research report on ALNY is available at:
Cara Therapeutics Inc.'s shares slid 1.97%, to close the day at $9.44 with a total trading volume of 1.14 million shares. The stock has advanced 16.69% in the past month and 43.90% over the previous three months. The Company's shares are trading 26.74% above their 50-day moving average and 47.62% above their 200-day moving average. Additionally, shares of Cara Therapeutics, which focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the US, have an RSI of 65.54.
On October 13th, 2016, research firm H.C. Wainwright initiated a 'Buy' rating on the Company's stock, issuing a target price of $20 per share.
On November 03rd, 2016, Cara Therapeutics reported a net loss of $11.5 million, or $0.42 per basic and diluted share, for Q3 2016 compared to a net loss of $4.8 million, or $0.19 per basic and diluted share, for Q3 2015. The Company did not recognize any revenue during Q3 2016, while total revenue recognized during Q3 2015 was $2.4 million, including $1.7 million of license and milestone fees revenue and $730,000 of collaborative revenue. Research and Development expenses were $9.7 million in Q3 2016 compared to $5.6 million in Q3 2015. The complimentary report on CARA can be downloaded at:
Shares in Maryland headquartered Emergent BioSolutions Inc. recorded a trading volume of 540,897 shares at the close of the last trading session, which was above their three months average volume of 464,780 shares. The stock ended the day 0.98% higher at $30.90. The Company's shares have advanced 2.35% in the last one month and 12.69% in the previous three months. The stock is trading above its 50-day moving average by 8.71%. Furthermore, shares of Emergent BioSolutions, which develops, manufactures, and sells specialized products to healthcare providers and governments in the US and internationally, have an RSI of 64.60.
On November 08th, 2016, Emergent BioSolutions announced the appointment of Kathryn C. Zoon, Ph.D. to its Board of Directors. Dr. Zoon is currently a Scientist Emeritus with the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. Dr. Zoon's affiliation with NIH spans four decades. Dr. Zoon also spent 23 years at the U.S. FDA. Visit us today and download our complete research report on EBS for free at:
Washington headquartered Alder Biopharmaceuticals Inc.'s stock finished Friday's session 5.93% higher at $32.15. A total volume of 700,885 shares was traded, which was higher than their three months average volume of 567,940 shares. The Company's shares have advanced 14.09% in the last one month and 2.91% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 7.38% and 19.38%, respectively. Furthermore, shares of Alder Biopharma, which discovers, develops, and commercializes therapeutic antibodies in the US and Australia, have an RSI of 63.10.
On October 27th, 2016, Alder Biopharmaceuticals for Q3 2016 did not record any revenues. Research and development expenses for Q3 2016 totaled $29.5 million compared to $22.9 million for Q3 2015. Net loss totaled $35.1 million, or $0.70 per share, for Q3 2016 compared to a net loss of $27.0 million, or $0.62 per share, on a fully-diluted basis, for Q3 2015.
On November 07th, 2016, research firm Aegis Capital initiated a 'Buy' rating on the Company's stock. Get free access to your technical report on ALDR at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA